Overview

Monogenic obesity genetic testing is used to identify genetic mutations associated with monogenic obesity. Unlike common obesity, which is influenced by a variety of factors including genetics, environment, and lifestyle, monogenic obesity is caused by mutations in a single gene that have a significant impact on weight regulation and metabolic processes. This test focuses on genes known to be associated with monogenic obesity, such as those affecting leptin signaling, the melanocortin pathway, and other important regulatory systems involved in appetite control and energy expenditure. By analyzing these genes, the test identifies specific mutated genes that contribute to severe early-onset obesity.

Discover the Genetic Roots of Obesity with Our Monogenic Gene Test

Protheragen has a long-standing commitment to obesity-related research, focusing on the development of cutting-edge anti-obesity therapies. Our research covers some important areas, including the Development of Anti-Obesity Therapeutic to find new treatment options, the anti-obesity therapeutics targets include but are not limited to Hormones and Peptides, Receptors, Enzymes and Proteins, Metabolic Regulators, and Signaling Molecules. At the same time, we promote the research and development of Anti-Obesity Therapies to provide patients with more effective treatment options, including but not limited to the development of Small Molecule Drugs, Gene Therapy, Cell Therapy, Antibody Therapy, Tissue Engineering Therapy, and Nanotherapy. We also conduct Preclinical Studies of Anti-Obesity Therapeutics to ensure the safety and efficacy of these new therapies.

Through these efforts, we expect to be able to contribute our efforts to solving the obesity problem and improving people's health and quality of life.

Genetic testing for monogenic obesity is usually performed using next-generation sequencing technology. This technology allows multiple genes to be tested simultaneously to look for mutations or variants associated with obesity. By sequencing the genome, the presence of mutations or variants associated with monogenic obesity is determined. Protheragen offers a wide range of monogenic obesity gene test services and Obesity Gene Panel Test Services with state-of-the-art technology, of which the genes included in our monogenic obesity gene test services are as follows.

Workflow

• DNA Extraction

  We treat the samples with a lysis buffer (e.g., one containing protease) that lyses the cells to release the DNA, removes the proteins, and precipitates the DNA, which is then lysed in an appropriate amount of Tris-EDTA (TE) buffer for subsequent analysis. We then measure the concentration and purity of the DNA using a spectrophotometer such as the NanoDrop. The integrity of the DNA is also checked by gel electrophoresis to ensure that there is no degradation.

• Sequencing Sample Preparation and Genetic Sequencing

  We use ultrasonic fragmentation or enzymatic digestion to reduce DNA fragments to a size suitable for sequencing (typically 200-600 bp) and attach specific adapters to the ends of the DNA fragments to facilitate subsequent sequencing and data analysis. The DNA fragments are then amplified by polymerase chain reaction (PCR) to increase the amount of DNA in the sample. Subsequently, we sequence the target genes using appropriate technologies, which include Sanger sequencing, whole exome sequencing, or next-generation sequencing.

• Data Analysis and Result Interpretation

  The pairs are analyzed for possible mutations or variants by comparing them with databases of known obesity-related mutations, or by sequencing the data using specialized genetic analysis software. Furthermore, we interpret the test results to determine if the mutation is related to obesity based on existing research.

Applications

• Test results can guide tailored management strategies, including the development of targeted therapies and personalized lifestyle interventions.
• The test contributes to a deeper understanding of the genetic basis of obesity and contributes to ongoing research into effective treatment methods and interventions.
• This facilitates the development of new treatment methods and interventions by providing insights into the genetic mechanisms underlying monogenic obesity.

Advantages

• With deep technical accumulation and expertise in targeting single-gene obesity, we ensure the accuracy and reliability of the test results.
• The use of the latest gene sequencing technologies, such as next-generation sequencing (NGS), provides higher sensitivity and accuracy compared to traditional methods.
• We provide comprehensive post-test services, including detailed result interpretation, counseling, and follow-up support.

Publication Data

Frequently Asked Questions

If the test result is negative, does it mean there is no genetic risk for obesity?

A negative result means that no known genetic variants associated with monogenic obesity have been detected, but it does not mean that there is no genetic risk for obesity at all. There may be unrecognized genetic factors or other factors that influence obesity.

What can the test results tell me?

The test results can provide valuable insights, including the presence of genetic variants associated with monogenic obesity, detailed information about specific genetic variants, their potential pathogenicity, and the assessment of family genetic risk.

Protheragen utilizes advanced genetic sequencing methods, bioinformatics analysis tools, and state-of-the-art laboratory equipment to provide efficient monogenic obesity gene test service. If you are interested in our monogenic obesity gene test service, please feel free to contact us!

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Obesity Gene Panel Test Service